Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jan 7, 2019 (8 years ago)

Cephalexin for Oral Suspension USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviation; manufacturing batch record could not be located

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Cephalexin for Oral Suspension USP, 250mg/5mL, 200 mL (when mixed), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India ---- NDC 68180-0124-02

Affected NDC 68180-0124-02

Compare with the code on your package — it is the most precise check available.

Drug: Cephalexin Category: Antibiotic

Recalling firm
Lupin Pharmaceuticals Inc.
NDC code
68180-0124-02
Origin
MD, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0380-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Cephalexin recalls

See all
Class II · Moderate risk

Cephalexin for Oral Suspension

Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 67877-544-68 D-0469-2025
Class II · Moderate risk

Cephalexin for Oral Suspension

Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 67877-544-88 D-0468-2025
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9207-1 D-0540-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states Each contains: cephalexin monohydrate, USP equivalent to 5g' on the back label instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9206-1 D-0539-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-8858-1 D-0538-2024

Other recalls by Lupin Pharmaceuticals Inc.

All 2019 recalls